|
What is a "specialty injectable"? The problem is, there is no clear answer. There is no standard list of specialty injectable drugs. It's an ongoing dilemma to determine if injectables are pharmacy costs, medical costs or both. Ventegra offers a solution to reduce confusion and increase savings.
New way to solve a very important problem.
The Ventegra Injectable Program (VIP) offers a package that provides a comprehensive and flexible solution to the injectable dilemma. The integrated medical and pharmacy claims engine used by Ventegra allows the adjudication of injectable claims into finite buckets that offer an unprecedented level of granularity to injectable drug use within a utilizing population. With VIP, an open crosswalk between NDCs, HCPCS codes (e.g., "J-codes") and diagnosis codes appropriately separates injectable claims into distinct medical and pharmaceutical charges, thus enabling more accuracy and clarity around pricing and reimbursement.
Our VIP acquisition cost-based injectable distribution program, utilizing Robo-Rebate (our fully-transparent Rebate Management System), provides a window into the actual net cost of these expensive pharmaceuticals. There isn't any incentive to "float the dose" or dispense more product to patients because our program's dispensing fees are not tied to volume. Ventegra's distribution program is also patterned after the Competitive Acquisition Program (CAP) favored by the federal government. |
|
True transparency provides clear savings.
VIP offers true transparency on all discounts, rebates and other fees negotiated with manufacturers and/or suppliers of injectable drugs. These price concessions are incorporated into the administration of the benefit design so that payors (i.e. HMOs, etc.), as well as patients needing injectable drugs, realize their fair share of the savings. VIP guarantees to do its share to help reduce the high cost of injectable drugs.
Let us show you how Ventegra's truth and integrity can work for you. |
